{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"88"},{"groupId":"OG003","value":"9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"119"},{"groupId":"OG003","value":"19"}],"units":"Participants"}],"description":"Participants were prompted to report injection-site experiences of pain, erythema, or swelling and were also asked to report any other injection-site adverse experiences","groups":[{"description":"GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A","id":"OG000","title":"GARDASIL 9 to 12 Years Old"},{"description":"GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A","id":"OG001","title":"Placebo 13 to 15 Years Old"},{"description":"GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A","id":"OG002","title":"GARDASIL 16 to 26 Years Old"},{"description":"Placebo to match GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A","id":"OG003","title":"Placebo 9 to 12 Years Old"}],"paramType":"NUMBER","populationDescription":"The analysis included all participants receiving at least 1 vaccination in study Phase A and who had postvaccination follow-up","reportingStatus":"POSTED","timeFrame":"Up to Day 5 after any vaccination in study Phase A","title":"Number of Participants With Injection-site Adverse Experiences","type":"PRIMARY","unitOfMeasure":"Participants"}